

Evaluation of Solithromycin (CEM-101), a Novel Fluroketolide, in Murine Infection Models

Abstract F1-2152

T. M. Murphy¹, S. Little¹, A. M. Slee¹, P. Fernandes²

¹ViviSource Laboratories, Inc. Waltham, MA ²Cempra Pharmaceuticals, Chapel Hill, NC

Background:

Solithromycin (CEM-101) has demonstrated significant activity against gram positive pathogens including *L. monocytogenes*, *E. faecalis* and macrolide resistant strains of *S. pneumoniae*.

Methods:

Efficacy was evaluated in an acute systemic infection model. CD-1 female mice were infected IP; CEM-101 or comparators were administered as a single oral dose 1 hr post infection. PD₅₀s were determined at 48 hr post infection. *L. monocytogenes* was delivered IV with treatment at 1 hr post infection. PD₅₀ determined at 72 hr post infection. CEM-101 was evaluated in a cyclophosphamide induced neutropenic mouse model of pneumonia infection. At 5, 24, and 36 hrs post lung infection with a *mef*(E), *erm*(B) resistant *S. pneumoniae* isolate, mice were orally dosed with CEM-101 or control drugs. Twenty-four hr after the end of treatment, the lungs were processed and CFU/gram of lung determined.

Results:

Mouse Systemic Infection Model PD ₅₀ (mg/kg)			
	CEM -101	Telithromycin	Clarithromycin
<i>S. pneumoniae</i> Serotype 19A (erythromycin R)	20.6 (15.7–25.4)	>30	>30
<i>S. pneumoniae</i> <i>mef</i> (E) & <i>erm</i> (B)	21.2 (12.9–29.4)	> 30	> 30
<i>E. faecalis</i> (macrolide susceptible)	11.5 (8.5-14.5)	10.9 (5.0-16.7)	21.8 (16.7-26.8)

In the systemic infection model, *L. monocytogenes* demonstrated PD₅₀ values for CEM-101, ampicillin, and azithromycin of 7.6, 55.1, and 11.6 mg/kg, respectively. Reduction in bio-load was evaluated against a resistant *S. pneumoniae* isolate in a neutropenic mouse pneumonia model. CEM-101 achieved 1, 2, and 3 log₁₀ reductions from controls at 30, 46.5 and 85 mg/kg, respectively. Telithromycin achieved a 1 and 2 log₁₀ reductions at 46 and > 100 mg/kg, respectively. Clarithromycin and Azithromycin were unable to effect a significant reduction in bio-load.

Conclusions:

CEM-101 has continued to demonstrate significant *in vivo* activity against susceptible and resistant bacteria strains.